ArticleInfection and drug resistance2026
A Successfully Treated Case of
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the pharmaceutical interventions conducted by clinical pharmacists in the case of a 59-year-old patient diagnosed with lung adenocarcinoma and a suspected infection, focusing on pathogen identification and the formulation of a safe and effective treatment plan. Methods: Through clinical consultation, pharmacists conducted an evaluation of the patient's underlying conditions and clinical manifestations, leading to the suspicion of a high probability of Mycobacterium chelonae infection. Consequently, they recommended a treatment regimen in accordance with guidelines for non-tuberculous mycobacterial infections, consisting of azithromycin 0.5 g and moxifloxacin 0.4 g administered orally once daily, accompanied by dynamic monitoring of therapeutic efficacy. Results: The patient became afebrile by day 3. At day 14, inflammatory markers had normalised, and no clinically significant adverse drug reactions were observed during short-term follow-up. Conclusion: In this case, PTseq supported early hypothesis generation and timely antimicrobial stewardship. The azithromycin-moxifloxacin regimen was associated with short-term clinical improvement; however, confirmatory microbiologic evidence, susceptibility guidance, and longer follow-up are needed before drawing generalized conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.